These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 33775894)

  • 1. Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study.
    Thomson MJ; Serper M; Khungar V; Weiss LM; Trinh H; Firpi-Morell R; Roden M; Loomba R; Barritt AS; Gazis D; Mospan AR; Fried MW; Reddy KR; Lok AS
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):458-460.e4. PubMed ID: 33775894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data.
    Loomba R; Wong R; Fraysse J; Shreay S; Li S; Harrison S; Gordon SC
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1149-1159. PubMed ID: 32372515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins Are Associated With a Decreased Risk of Severe Liver Disease in Individuals With Noncirrhotic Chronic Liver Disease.
    Sharma R; Simon TG; Hagström H; Lochhead P; Roelstraete B; Söderling J; Verna EC; Emond J; Ludvigsson JF
    Clin Gastroenterol Hepatol; 2024 Apr; 22(4):749-759.e19. PubMed ID: 37121528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease.
    Doumas M; Imprialos K; Dimakopoulou A; Stavropoulos K; Binas A; Athyros VG
    Curr Pharm Des; 2018; 24(38):4587-4592. PubMed ID: 30652643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes.
    Nascimbeni F; Pellegrini E; Lugari S; Mondelli A; Bursi S; Onfiani G; Carubbi F; Lonardo A
    Atherosclerosis; 2019 May; 284():66-74. PubMed ID: 30875495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic fatty liver disease and statins.
    Tziomalos K; Athyros VG; Paschos P; Karagiannis A
    Metabolism; 2015 Oct; 64(10):1215-23. PubMed ID: 26234727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial.
    Bril F; Portillo Sanchez P; Lomonaco R; Orsak B; Hecht J; Tio F; Cusi K
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2950-2961. PubMed ID: 28575232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease.
    Lee TY; Wu JC; Yu SH; Lin JT; Wu MS; Wu CY
    Int J Cancer; 2017 Oct; 141(7):1307-1314. PubMed ID: 28509327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statin Use and Reduced Hepatocellular Carcinoma Risk in Patients With Nonalcoholic Fatty Liver Disease.
    Zou B; Odden MC; Nguyen MH
    Clin Gastroenterol Hepatol; 2023 Feb; 21(2):435-444.e6. PubMed ID: 35158055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.
    Alexander M; Loomis AK; van der Lei J; Duarte-Salles T; Prieto-Alhambra D; Ansell D; Pasqua A; Lapi F; Rijnbeek P; Mosseveld M; Waterworth DM; Kendrick S; Sattar N; Alazawi W
    BMC Med; 2019 May; 17(1):95. PubMed ID: 31104631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statin use is not associated with presence of and severity of nonalcoholic fatty liver disease.
    Oni ET; Sinha P; Karim A; Martin SS; Blaha MJ; Agatston AS; Blumenthal RS; Meneghelo RS; Conceiçao RD; Santos RD; Nasir K
    Arch Med Res; 2014 Jan; 45(1):52-7. PubMed ID: 24333254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescription of statins in suspected non-alcoholic fatty liver disease and high cardiovascular risk, a population-based study.
    van den Berg EH; Wolters AAB; Dullaart RPF; Moshage H; Zurakowski D; de Meijer VE; Blokzijl H
    Liver Int; 2019 Jul; 39(7):1343-1354. PubMed ID: 30968536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.
    Younossi ZM; Marchesini G; Pinto-Cortez H; Petta S
    Transplantation; 2019 Jan; 103(1):22-27. PubMed ID: 30335697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statins Are Underused in Women With NAFLD After Cardiovascular Events Compared With Matched Control Subjects.
    Shang Y; Hagström H
    Clin Gastroenterol Hepatol; 2023 May; 21(5):1359-1361.e2. PubMed ID: 35339670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action.
    Zhang S; Ren X; Zhang B; Lan T; Liu B
    Molecules; 2024 Apr; 29(8):. PubMed ID: 38675679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Advances in diagnosis and treatment of nonalcoholic fatty liver disease].
    Zhu C; Zhou D; Fan J
    Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):81-4. PubMed ID: 26983471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.